Methuselah Fund

The CEO, who also founded the Methuselah Foundation, and the Managing Director lead the investment process, supported by a deep bench of executive and scientific advisors from the longevity field. Specific deal-level authority is not publicly detailed. The firm's website does not name its leadership beyond their functional roles — CEO and Managing Director — omitting individuals' full names.

Deal flow comes almost entirely through the network of the Methuselah Foundation, a nonprofit the CEO launched 16 years prior to the Fund. The Foundation's scientific collaborators and its defined longevity strategies drive proprietary access to early-stage biopharma and biotech startups. This shared-origin structure means the Fund sees companies before typical venture firms, often at the translational stage.

The portfolio spans pre-clinical to late-stage clinical biotech. Holdings include Leucadia Therapeutics, which is developing an Alzheimer's surgical procedure, OncoSenX, a late-stage pre-clinical cancer company, and others moving toward human data. The firm invests across the continuum where the underlying biology is mature enough for translation into a therapeutic or device.

Methuselah Fund is the for-profit venture arm of the Methuselah Foundation, a longevity-science nonprofit active for 16 years. The CEO runs both entities. The Fund invests in companies whose science often originates in the Foundation's ecosystem, creating a capital pipeline from foundational research to clinical development.